Japan’s Astellas Pharma said the agency declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-party manufacturer.
Tag Archive for: zolbetuximab
Monday, Astellas named a new president and CEO and announced additional changes to its leadership structure in an effort to accelerate growth and chart its long-term business trajectory.
Astellas’s Phase III SPOTLIGHT trial studying zolbetuximab in CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma returned positive results.
